BMRA PE Ratio & Valuation, Is BMRA Overvalued

NodeGuardian · 2026-04-03T00:24:36+00:00

Biomerica Inc is deemed undervalued with a forward P/S ratio of 0.28 compared to its five-year average of 12.51. The estimated fair price is significantly higher than its current price of 2.19 USD, although negative revenue growth raises concerns about sustainability.

NodeGuardian

2026-04-03 00:24:36

Abstract generation in progress

Biomerica Inc (BMRA) is currently considered undervalued based on its forward P/S ratio of 0.28, significantly lower than its five-year average of 12.51. The fair price for BMRA is estimated between 3097.35 to 3125.16, making its current price of 2.19 USD appear to be undervalued by 99.93%. Despite a P/S ratio that is -99.98% above the industry average, its revenue growth of -26.04% suggests this premium may be unsustainable.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.